KontRASt-03: A Phase Ib/II multicenter open-label platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation
Brief description of study
KontRASt-03: A Phase Ib/II, multicenter, open-label platform study of JDQ443 with select combinations in patients with advanced solid tumor harboring the KRAS G12C mutation
Clinical Study Identifier: s21-01557
ClinicalTrials.gov Identifier: NCT05358249
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.